Ninds' drug manufacturing and formulation program (DMFP): shamloo-selective CB2 agonist; MRI research INC:1186811 [26-000042]
Active Awarded Last action
- Contract number
- 75N98026F00002
- Awardee
-
Mriglobal UEI HKQHNFKNKL15
- Awarding agency
-
Office of Logisitics and Acquisition Operations
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,363,408
Award facts
- Opportunity
-
- NIHNINDS260001 Solicitation number
- Contract value 54% obligated
-
- $1,363,408.00 Current, with exercised options
- $2,534,752.00 Potential, with all options
- Completion date 4% complete
-
- Current, with exercised options
- Potential, with all options
- Funding agency
- National Institute of Neurological Disorders and Stroke National Institutes of Health, Department of Health and Human Services
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 4 offers Multiple Award, Fair Opportunity
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Kansas City, MO 64110, USA
- Legislative mandates
-
- Service Contract Act FAR subpart 22.10
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
About this award
The National Institute of Neurological Disorders and Stroke issued a delivery order to Mriglobal on August 15, 2026, with a ceiling value of $2,534,752, for drug manufacturing and formulation under the NINDS Drug Manufacturing and Formulation Program, specifically for a selective CB2 agonist.
The order is issued under the NINDS $49.99 million multiple-award Drug Manufacturing and Formulation Program contract (awarded May 2026, through May 2036). Place of performance is Kansas City, MO. Period of performance extends through August 14, 2032. The order carries cost-plus-fixed-fee pricing and was issued with no set-aside. Mriglobal is a large, unrestricted nonprofit research organization based in Kansas City and does business as Midwest Research Institute, operating sophisticated laboratory and pharmaceutical manufacturing facilities across multiple locations including headquarters with 225,000 square feet and 60,000 square feet of dedicated laboratory space.
Quick answers
Who was awarded contract 75N98026F00002?
75N98026F00002 was awarded to Mriglobal by Office of Logisitics and Acquisition Operations (National Institutes of Health) on August 15, 2026.
How much is contract 75N98026F00002 worth?
The government has obligated $1,363,408 on 75N98026F00002. Its potential value, with all options, is $2,534,752.
Which agency awarded contract 75N98026F00002?
Office of Logisitics and Acquisition Operations (National Institutes of Health) awarded 75N98026F00002, with funding from National Institute of Neurological Disorders and Stroke (National Institutes of Health).
Is contract 75N98026F00002 an order under another contract?
Yes. 75N98026F00002 is a delivery order under 75N98026D00014, an indefinite delivery contract.
Was contract 75N98026F00002 competed?
The extent of competition for 75N98026F00002 was full and open competition. The government received 4 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award